Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inezetamab Monotherapy and in Combination with Zeluvalimab in Advanced Solid Tumors
NCT04727554Phase 1Completed
- Sponsor
- Amgen
- Start
- Apr 2021
- Primary completion
- Jun 2023
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 10
01
Overview
Phase 1, open-label trial of inezetamab in solid tumor (advanced stage) (4 arms), sponsored by Amgen. Primary endpoints: Dose Limiting Toxicities and Treatment-emergent Adverse Events. Started Apr 2021; status: completed.
02
Drugs
inezetamab
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04727554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04727554.